Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma

Kristoph Jahnke, Leslie L. Muldoon, Csanad G. Varallyay, Seth J. Lewin, Robert D. Brown, D. Kraemer, Carole Soussain, Edward A. Neuwelt

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

To determine the efficacy of methotrexate and/or rituximab in a CNS lymphoma model and to evaluate MRI modalities for monitoring efficacy, we inoculated female athymic nude rats (rnu/rnu) intracerebrally with human MC116 B-lymphoma cells. Between days 16 and 26, rats were randomized to receive intravenous (IV) treatment with (1) saline (controls, n = 15), (2) methotrexate 1,000 mg/m2 (n = 6), (3) rituximab 375 mg/m2 (n = 6), or (4) rituximab plus methotrexate (n = 6). T2/fluid-attenuated inversion recovery (FLAIR) and gadolinium contrast-enhanced T1 MRI sequences were performed prior to and 1 week after treatment. IV rituximab gave an objective tumor response in four of six animals (>50% reduction in tumor volume comparing pre- and posttreatment T2/FLAIR MRI) and resulted in stable disease (50%-125% of baseline) in another animal. The percent change in tumor volume on T2/FLAIR images was significantly different in the control versus rituximab group (p = 0.0051). IV methotrexate slowed tumor growth, compared to controls, but only one of six animals had an objective response. In untreated controls, tumor histological volumes correlated well with T2/ FLAIR or contrast-enhanced T1 images (r = 0.877). In the treatment groups, T2/FLAIR correlation was good, but the gadolinium-enhanced T1 MRI was not significantly correlated with histology (r = 0.19). The MC116 CNS lymphoma model seems valuable for preclinical testing of efficacy and toxicity of treatment regimens. IV rituximab was highly effective, but methotrexate was only minimally effective. T2/FLAIR was superior to contrast-enhanced T1 for monitoring efficacy.

Original languageEnglish
Pages (from-to)503-513
Number of pages11
JournalNeuro-Oncology
Volume11
Issue number5
DOIs
Publication statusPublished - Oct 2009

Fingerprint

Nude Rats
Methotrexate
Lymphoma
Tumor Burden
Gadolinium
B-Cell Lymphoma
Rituximab
Neoplasms
Histology
Therapeutics
Growth

Keywords

  • Central nervous system lymphoma
  • Methotrexate
  • MRI
  • Rat model
  • Rituximab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Clinical Neurology

Cite this

Jahnke, K., Muldoon, L. L., Varallyay, C. G., Lewin, S. J., Brown, R. D., Kraemer, D., ... Neuwelt, E. A. (2009). Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma. Neuro-Oncology, 11(5), 503-513. https://doi.org/10.1215/15228517-2008-119

Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma. / Jahnke, Kristoph; Muldoon, Leslie L.; Varallyay, Csanad G.; Lewin, Seth J.; Brown, Robert D.; Kraemer, D.; Soussain, Carole; Neuwelt, Edward A.

In: Neuro-Oncology, Vol. 11, No. 5, 10.2009, p. 503-513.

Research output: Contribution to journalArticle

Jahnke, K, Muldoon, LL, Varallyay, CG, Lewin, SJ, Brown, RD, Kraemer, D, Soussain, C & Neuwelt, EA 2009, 'Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma', Neuro-Oncology, vol. 11, no. 5, pp. 503-513. https://doi.org/10.1215/15228517-2008-119
Jahnke, Kristoph ; Muldoon, Leslie L. ; Varallyay, Csanad G. ; Lewin, Seth J. ; Brown, Robert D. ; Kraemer, D. ; Soussain, Carole ; Neuwelt, Edward A. / Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma. In: Neuro-Oncology. 2009 ; Vol. 11, No. 5. pp. 503-513.
@article{04fae20930b647c4b1ef11bd96c4b56b,
title = "Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma",
abstract = "To determine the efficacy of methotrexate and/or rituximab in a CNS lymphoma model and to evaluate MRI modalities for monitoring efficacy, we inoculated female athymic nude rats (rnu/rnu) intracerebrally with human MC116 B-lymphoma cells. Between days 16 and 26, rats were randomized to receive intravenous (IV) treatment with (1) saline (controls, n = 15), (2) methotrexate 1,000 mg/m2 (n = 6), (3) rituximab 375 mg/m2 (n = 6), or (4) rituximab plus methotrexate (n = 6). T2/fluid-attenuated inversion recovery (FLAIR) and gadolinium contrast-enhanced T1 MRI sequences were performed prior to and 1 week after treatment. IV rituximab gave an objective tumor response in four of six animals (>50{\%} reduction in tumor volume comparing pre- and posttreatment T2/FLAIR MRI) and resulted in stable disease (50{\%}-125{\%} of baseline) in another animal. The percent change in tumor volume on T2/FLAIR images was significantly different in the control versus rituximab group (p = 0.0051). IV methotrexate slowed tumor growth, compared to controls, but only one of six animals had an objective response. In untreated controls, tumor histological volumes correlated well with T2/ FLAIR or contrast-enhanced T1 images (r = 0.877). In the treatment groups, T2/FLAIR correlation was good, but the gadolinium-enhanced T1 MRI was not significantly correlated with histology (r = 0.19). The MC116 CNS lymphoma model seems valuable for preclinical testing of efficacy and toxicity of treatment regimens. IV rituximab was highly effective, but methotrexate was only minimally effective. T2/FLAIR was superior to contrast-enhanced T1 for monitoring efficacy.",
keywords = "Central nervous system lymphoma, Methotrexate, MRI, Rat model, Rituximab",
author = "Kristoph Jahnke and Muldoon, {Leslie L.} and Varallyay, {Csanad G.} and Lewin, {Seth J.} and Brown, {Robert D.} and D. Kraemer and Carole Soussain and Neuwelt, {Edward A.}",
year = "2009",
month = "10",
doi = "10.1215/15228517-2008-119",
language = "English",
volume = "11",
pages = "503--513",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma

AU - Jahnke, Kristoph

AU - Muldoon, Leslie L.

AU - Varallyay, Csanad G.

AU - Lewin, Seth J.

AU - Brown, Robert D.

AU - Kraemer, D.

AU - Soussain, Carole

AU - Neuwelt, Edward A.

PY - 2009/10

Y1 - 2009/10

N2 - To determine the efficacy of methotrexate and/or rituximab in a CNS lymphoma model and to evaluate MRI modalities for monitoring efficacy, we inoculated female athymic nude rats (rnu/rnu) intracerebrally with human MC116 B-lymphoma cells. Between days 16 and 26, rats were randomized to receive intravenous (IV) treatment with (1) saline (controls, n = 15), (2) methotrexate 1,000 mg/m2 (n = 6), (3) rituximab 375 mg/m2 (n = 6), or (4) rituximab plus methotrexate (n = 6). T2/fluid-attenuated inversion recovery (FLAIR) and gadolinium contrast-enhanced T1 MRI sequences were performed prior to and 1 week after treatment. IV rituximab gave an objective tumor response in four of six animals (>50% reduction in tumor volume comparing pre- and posttreatment T2/FLAIR MRI) and resulted in stable disease (50%-125% of baseline) in another animal. The percent change in tumor volume on T2/FLAIR images was significantly different in the control versus rituximab group (p = 0.0051). IV methotrexate slowed tumor growth, compared to controls, but only one of six animals had an objective response. In untreated controls, tumor histological volumes correlated well with T2/ FLAIR or contrast-enhanced T1 images (r = 0.877). In the treatment groups, T2/FLAIR correlation was good, but the gadolinium-enhanced T1 MRI was not significantly correlated with histology (r = 0.19). The MC116 CNS lymphoma model seems valuable for preclinical testing of efficacy and toxicity of treatment regimens. IV rituximab was highly effective, but methotrexate was only minimally effective. T2/FLAIR was superior to contrast-enhanced T1 for monitoring efficacy.

AB - To determine the efficacy of methotrexate and/or rituximab in a CNS lymphoma model and to evaluate MRI modalities for monitoring efficacy, we inoculated female athymic nude rats (rnu/rnu) intracerebrally with human MC116 B-lymphoma cells. Between days 16 and 26, rats were randomized to receive intravenous (IV) treatment with (1) saline (controls, n = 15), (2) methotrexate 1,000 mg/m2 (n = 6), (3) rituximab 375 mg/m2 (n = 6), or (4) rituximab plus methotrexate (n = 6). T2/fluid-attenuated inversion recovery (FLAIR) and gadolinium contrast-enhanced T1 MRI sequences were performed prior to and 1 week after treatment. IV rituximab gave an objective tumor response in four of six animals (>50% reduction in tumor volume comparing pre- and posttreatment T2/FLAIR MRI) and resulted in stable disease (50%-125% of baseline) in another animal. The percent change in tumor volume on T2/FLAIR images was significantly different in the control versus rituximab group (p = 0.0051). IV methotrexate slowed tumor growth, compared to controls, but only one of six animals had an objective response. In untreated controls, tumor histological volumes correlated well with T2/ FLAIR or contrast-enhanced T1 images (r = 0.877). In the treatment groups, T2/FLAIR correlation was good, but the gadolinium-enhanced T1 MRI was not significantly correlated with histology (r = 0.19). The MC116 CNS lymphoma model seems valuable for preclinical testing of efficacy and toxicity of treatment regimens. IV rituximab was highly effective, but methotrexate was only minimally effective. T2/FLAIR was superior to contrast-enhanced T1 for monitoring efficacy.

KW - Central nervous system lymphoma

KW - Methotrexate

KW - MRI

KW - Rat model

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=70349624594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349624594&partnerID=8YFLogxK

U2 - 10.1215/15228517-2008-119

DO - 10.1215/15228517-2008-119

M3 - Article

C2 - 19158414

AN - SCOPUS:70349624594

VL - 11

SP - 503

EP - 513

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 5

ER -